glp-1 news today november 2025 Receptor Agonists and vision risk Boston, USA. 16th Nov, 2025.

Future research should prioritize robust retention protocols, transparent reporting of attrition, and appropriate statistical methodologies to mitigate these concerns

This showed us that GLP-1 and GIP are not as effective in shutting down glucagon and stimulating insulin secretion in patients with kidney disease compared to controls, suggesting increased resistance to their action in CKD, Ahmadi added

"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept"

All this is to say that we would expect the prevalence of coverage of GLP-1s in the individual market to be quite low compared to the self-insured employer market